Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Summary 
Mr. Daniel E. Geffken is a CFO, Principal Financial & Accounting Officer at OPY Acquisition Corp. I, a Chief Financial Officer at Phoenix Biotech Acquisition Corp., a Chief Financial & Accounting Officer at Eloxx Pharmaceuticals, Inc., a Chief Financial Officer at CalciMedica, Inc., a Chief Financial Officer at DermBiont, Inc., a Chief Financial Officer at Palvella Therapeutics, Inc., a Chief Financial Officer at Privo Technologies, Inc., a Chief Financial Officer at Zikani Therapeutics, Inc., an Independent Director at Windtree Therapeutics, Inc., a Chief Financial Officer at Apic Bio, Inc., a Chief Financial Officer at Vigeo Therapeutics, Inc., a Chief Financial Officer at ProMIS Neurosciences, Inc., a Chief Financial Officer at Antolrx, Inc., a Chief Financial Officer & Director at Elicio Therapeutics, Inc., a Co-Managing Director at Danforth Advisors LLC, a Chief Financial Officer at Artax Biopharma, Inc., a Chief Financial Officer at Clear Creek Bio, Inc., a Chief Financial Officer at GenePeeks, Inc., a Chief Financial Officer at Matrivax Research & Development Corp., a Chief Financial Officer at Myeloid Therapeutics, Inc., a Chief Financial Officer at Nemucore Medical Innovations, Inc., a Chief Financial Officer at Prilenia Therapeutics Development Ltd., a Chief Financial Officer at United Neuroscience Ltd., a Chief Financial Officer at Vaxxinity, Inc. and a Chief Financial Officer at Windgap Medical, Inc.

He is on the Board of Directors at Windtree Therapeutics, Inc., Elicio Therapeutics, Inc. and SG DAN Holdings LLC. Mr. Geffken was previously employed as a Chief Financial Officer by Locust Walk Acquisition Corp., a Chief Financial Officer by Cabaletta Bio, Inc., an Independent Director by Arcturus Therapeutics Ltd., a Chief Financial Officer by Stealth BioTherapeutics Corp., a Chief Financial Officer by Apellis Pharmaceuticals, Inc.,


Current positions of Daniel E. Geffken 
NameTitle Since
Phoenix Biotech Acquisition Corp.
(Investment Holding Companies)
Chief Financial Officer 2021
OPY Acquisition Corp. I
(Investment Holding Companies)
Chief Financial Officer & Secretary 2021
ProMIS Neurosciences, Inc.
(Biotechnology & Medical Research)
Chief Financial Officer 2017
Windtree Therapeutics, Inc.
(Biotechnology & Medical Research)
Independent Director 2019
Eloxx Pharmaceuticals, Inc.
(Biotechnology & Medical Research)
Chief Financial & Accounting Officer 2021
Antolrx, Inc. Chief Financial Officer 2016
Matrivax Research & Development Corp. Chief Financial Officer -
Myeloid Therapeutics, Inc. Chief Financial Officer -
Prilenia Therapeutics Development Ltd. Chief Financial Officer -
Privo Technologies, Inc. Chief Financial Officer 2020
Apic Bio, Inc. Chief Financial Officer 2018
Clear Creek Bio, Inc. Chief Financial Officer -
DermBiont, Inc. Chief Financial Officer 2020
Palvella Therapeutics, Inc. Chief Financial Officer 2020
United Neuroscience Ltd. Chief Financial Officer -
Vigeo Therapeutics, Inc. Chief Financial Officer 2017
GenePeeks, Inc. Chief Financial Officer -
Nemucore Medical Innovations, Inc. Chief Financial Officer -
Zikani Therapeutics, Inc. Chief Financial Officer 2019
Windgap Medical, Inc. Chief Financial Officer -
Artax Biopharma, Inc. Chief Financial Officer -
CalciMedica, Inc. Chief Financial Officer 2020
SG DAN Holdings LLC Director -
Elicio Therapeutics, Inc. Director 2014
Danforth Advisors LLC Co-Managing Director 2011


Holdings of Daniel E. Geffken 
NameEquities%Valuation
ProMIS Neurosciences, Inc. (PMN)
(Biotechnology & Medical Research)
5,8520.081%37,968 USD
Eloxx Pharmaceuticals, Inc. (ELOX)
(Biotechnology & Medical Research)
50,0000.058%13,500 USD
Windtree Therapeutics, Inc. (WINT)
(Biotechnology & Medical Research)
7,0690.024%2,948 USD


Daniel E. Geffken: Personal Network 
Most Read News 
07/29MARK ZUCKERBERG : Company's pandemic-era forecast was too rosy
RE
07/29CATHIE WOOD : Wood's ARK fund on track for first monthly gain since Oct as risky stocks rally
RE
08/06ELON MUSK : Musk says Twitter deal should go ahead if it provides proof of real accounts
RE
08/04JACK DORSEY : Dorsey-led Block posts loss for second quarter
RE
08/02ELON MUSK : Twitter queries banks on Musk's attempts to undermine $44 billion deal
RE
08/09ELON MUSK : Elon Musk sells 7.92 million Tesla shares worth $6.9 billion - SEC filing
RE
07/28JACK MA : Jack Ma plans to give up control of Ant Group - WSJ
RE
08/01DAVID EINHORN : Einhorn's Greenlight takes stake in Twitter - letter
RE
08/02STEPHEN KING : Horror author Stephen King says in publishing trial that consolidation hurts competition
RE
08/01STEPHEN KING : Stephen King goes to bat for U.S. gov't in case against book publishing mega-merger
RE
More news


© 2022 People and Ownership :   
Daniel E. Geffken : Connections